FDA Warns Empower Pharmacy Over Mass Copying Of GLP-1 Drugs
The Food and Drug Administration on Sept. 18 issued a warning letter to Empower Pharmacy over its compounding of GLP-1 drugs, escalating a fight over whether compounding has become illegal mass production.[1]
The letter was posted online Sept. 22 and followed a November 2025 FDA inspection.[1] FDA said inspectors found Empower made copies of tirzepatide and semaglutide in "inordinate amounts" and that many orders lacked or duplicated required prescriber statements.[1]
Eli Lilly has sued Empower, accusing the pharmacy of mass-manufacturing standardized knockoffs of Zepbound and Mounjaro; Empower denies the claims.[1] The FDA action is its first formal step into when compounding for GLP-1 drugs crosses into unlawful mass production after shortages ended in 2025.[1]
The dispute raises questions about patient access to cheaper GLP-1 weight-loss drugs and whether regulators will prioritize safety or availability as enforcement proceeds.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On September 18, 2026, FDA issued a warning letter to Empower Pharmacy, posted online September 22, over compounded GLP-1 products.
- The letter followed a November 2025 inspection and alleged Empower made copies of tirzepatide and semaglutide drugs in "inordinate amounts."
- FDA said many Empower orders lacked or duplicated required prescriber statements that the compounded versions would be significantly different for individual patients.
- Empower is already facing an Eli Lilly lawsuit alleging it mass-manufactures standardized knockoffs of Zepbound and Mounjaro; Empower denies the claims.
- The enforcement action is FDA's first step into the dispute over when compounding for GLP-1 drugs becomes unlawful mass production after shortages ended in 2025.
📰 Source Timeline (1)
Follow how coverage of this story developed over time